Home > Investor Relations

Investor Relations

Welcome to Giant Biogene Investor Relations

We are a leader in the bioactive ingredient-based professional skin treatment product industry in China. Our years of R&D on bioactive ingredients and integrated business model enable us to achieve the technological and market leadership positions in the industry. We design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. We also develop and manufacture rare ginsenosides technology-based functional foods. We utilize proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house.

80
Patents and Pending Patent Applications
(As of the Latest Practicable Date)
2000
Xi'an Giant Biogene was incorporated in
2
Synthetic Biology Technology

We are a leader in the bioactive ingredient-based professional skin treatment product industry in China. Our years of R&D on bioactive ingredients and integrated business model enable us to achieve the technological and market leadership positions in the industry. We design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient.

We also develop and manufacture rare ginsenosides technology-based functional foods. We utilize proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house.

  • Monthly Returns 
    Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 May 2023
    2023-06-02
  • Monthly Returns 
    Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2023
    2023-05-03
  •  
    FORM OF PROXY FOR USE AT 2022 ANNUAL GENERAL MEETING TO BE HELD ON JUNE 13, 2023
    2023-04-26
  • Announcements and Notices 
    NOTICE OF ANNUAL GENERAL MEETING
    2023-04-26
  • Circulars 
    PROPOSED RE-APPOINTMENT OF AUDITOR PROPOSED RE-ELECTION OF DIRECTORS PROPOSED GRANT OF GENERAL MANDATES TO REPURCHASE SHARES AND ISSUE SHARES AND NOTICE OF ANNUAL GENERAL MEETING
    2023-04-26
  •  
    ANNUAL REPORT 2022
    2023-04-26
  • Monthly Returns 
    Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2023
    2023-04-03
  • Announcements and Notices 
    ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2022
    2023-03-27
  • Announcements and Notices 
    DATE OF BOARD MEETING
    2023-03-15
  • Monthly Returns 
    Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 February 2023
    2023-03-03

Subscribe successfully!
Lang
En